Company news
Palvella Therapeutics, Inc. news in 2025
Palvella Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
December 16, 2025
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies
December 15, 2025
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-app...
December 14, 2025
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 11, 2025
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
November 6, 2025
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
November 5, 2025
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
November 4, 2025
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
October 13, 2025
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
September 24, 2025
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
September 17, 2025
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
September 15, 2025
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
September 3, 2025
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
August 28, 2025
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
August 7, 2025
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 5, 2025
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
June 30, 2025
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
June 23, 2025
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
June 18, 2025
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
June 9, 2025
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
May 27, 2025
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 15, 2025
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
May 8, 2025
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
May 5, 2025
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
April 23, 2025
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
April 22, 2025
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
April 11, 2025
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
April 4, 2025
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
April 2, 2025
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
March 31, 2025
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
March 18, 2025
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
February 25, 2025
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
February 9, 2025
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
January 9, 2025
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
January 7, 2025
Calls in 2025
- Palvella Therapeutics (NASDAQ:PVLA) Q3 2025 Earnings Call
Nov 11, 2025
Transcript - Palvella Therapeutics (NASDAQ:PVLA) Q2 2025 Earnings Call
Aug 14, 2025
Transcript - Palvella Therapeutics (NASDAQ:PVLA) Q1 2025 Earnings Call
May 15, 2025
Transcript - Palvella Therapeutics (NASDAQ:PVLA) Q4 2024 Earnings Call
Mar 31, 2025
Transcript
Decks in 2025
- Technical Presentation (December 2025)
Technical · 23 slides · Dec 15, 2025
- Q3 2025 Earnings Presentation
Earnings · 19 slides · Nov 11, 2025
- Q3 2025 Earnings Presentation
Earnings · 19 slides · Nov 10, 2025
- Investor Presentation (November 2025)
Investor deck · 23 slides · Nov 5, 2025
- Investor Presentation (September 2025)
Investor deck · 48 slides · Sep 3, 2025
- Q2 2025 Earnings Presentation
Earnings · 12 slides · Aug 14, 2025
- Q1 2025 Earnings Presentation
Earnings · 16 slides · May 15, 2025
- FY2024 Earnings Presentation
Earnings · 27 slides · Mar 31, 2025
- Investor Presentation (March 2025)
Investor deck · 37 slides · Mar 4, 2025
- Investor Presentation (January 2025)
Investor deck · 38 slides · Jan 13, 2025